Give Patients a Taste of Their Own Medicine

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

The Asthma and Allergy Foundation of America recently released its annual Allergy Capitals™ report. Which cities are most challenging for patients with seasonal allergies?

What is the optimal duration for immunotherapy? Can intranasal steroids be combined with LRTAs? Test your allergy IQ.

An experimental cell-based therapy induces permanent allergen-specific immunologic tolerance to prevent IgE-mediated allergy.

Why has the number of food allergies increased but overall sensitization to food allergens remained static?